[Treatment of Crohn's disease: step-up or top-down?].
Herrlinger
K
K
Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Robert-Bosch-Krankenhaus, Stuttgart. klaus.herrlinger@rbk.de
Stange
E F
EF
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003082:Colectomy; D003424:Crohn Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D016099:Endoscopy, Gastrointestinal; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008134:Long-Term Care; D012008:Recurrence; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab